Steroid-toxicity
can now be measured
in the clinic.
It’s time clinicians in practice were equipped with a standardized measure of steroid-toxicity.
If you ask the doctor and patient what they want most of all, their unanimous answer will be, "not to have to use steroids."
For more than 70 years glucocorticoids have been both poison and panacea - with patients knowing the very drugs treating their conditions are also doing long-term damage.
While there are improved dosing regimens and an increasing number of steroid-sparing drugs and biologics, until now clinicians have been without a standardized measure to track the impacts of steroid-toxicity.
In the value-based care environment, the Steritas GTI provides a longitudinal and quantitative assessment of steroid-toxicity. The GTI measures toxicity in steroid-dependent patients so physicians can be vigilant in preventing treatment induced harm.
The GTI can:
- Detect even subtle changes in toxicity between clinic visits.
- Alert a provider to toxicity in specific health domains e.g. GTI blood pressure scores and bone mineral density scores that may indicate an increased risk of stroke or fracture.
“Using the GTI to monitor all people receiving glucocorticoids within a health care system would enable us to better understand the effects of glucocorticoid side effects at a population health scale, improve outcomes for patients and reduce health care inequity.”
Sherwood Brown, MD PHD MBA
Professor of Psychiatry
Vice Chair for Clinical Research
Chief of the Division of Clinical Neuroscience
Director of the Psychoneuroendocrine Research Program
UT Southwestern Medical Center
“What you gain by using the Steritas GTI is a systematic way of assessing steroid-toxicity.”
David Jayne, MD
Professor of Clinical Autoimmunity, University of Cambridge,
and Director, Vasculitis and Lupus Service, Addenbrooke’s Hospital
“Being able to show that you can decrease the effects of glucocorticoid toxicity is a huge step, making the benefits of a new drug more understandable as clinicians and physicians use it.”
Sudhakar Sridharan, MD
Vice President, Global Product Development, Imm/Rheum/Inflam/Clinical Research
PPD, part of ThermoFisher Scientific
“You want to evaluate activity, you want to evaluate damage, permanent damage, you want to evaluate quality of life. That’s where the GTI fits in as part of a holistic approach to patient assessment.”
David Jayne, MD
Professor of Clinical Autoimmunity, University of Cambridge,
and Director, Vasculitis and Lupus Service, Addenbrooke’s Hospital
Could the Steritas GTI be a useful outcome measure for your patients?
Contact us to find out.
